Kymera Therapeutics, Inc. (KYMR) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Chimera Therapeutics (KYMR) Q1 2026: Gilead Triggers $45M Milestone as KT200 Advances, Extending Cash Runway to 2029
April 30, 2026
-
Chimera Therapeutics (KYMR) Q4 2025: $1.6B Cash Extends Runway, KT621 Drives Paradigm Shift in Type 2 Disease
February 26, 2026
-
Kymera Therapeutics (KYMR) Q3 2025: $978M Cash Runway Powers STAT6 and IRF5 Pipeline Milestones
November 04, 2025
-
Chimera Therapeutics (KYMR) Q2 2025: $1B Cash Runway Extends Pipeline Acceleration Across Immunology Franchise
August 11, 2025
-
Kymera (KYMR) Q1 2025: $20M Milestone Validates Immunology Focus as IRF5 and STAT6 Pipeline Accelerates
July 07, 2025